IRCCS Humanitas Research Hospital & Humanitas University
Published February 4, 2021 | Version v1
Dataset Restricted

Dataset related to article "Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma"

Authors/Creators

  • 1. IRCCS Humanitas Research Hospital
  • 2. Institut Paoli Calmettes
  • 3. Hospital Saint-Antoine

Description

This record contains data related to article "Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma"

We report on 59 Hodgkin lymphoma patients undergoing haploidentical stem cell
transplantation (SCT; haplo-SCT) with posttransplant cyclophosphamide (PTCy) as graftversus-
host disease (GVHD) prophylaxis, comparing outcomes based on pretransplant
exposure to checkpoint inhibitors (CPIs). Considering pretransplant characteristics, the
2 cohorts (CPI 5 29 patients vs no-CPI 5 30 patients) were similar, except for the number
of prior lines of therapy (6 vs 4; P , .001). With a median follow-up of 26 months (range,
7.5-55 months), by univariate analysis, the 100-day cumulative incidence of grade 2-4 acute GVHD
was 41% in the CPI group vs 33% in the no-CPI group (P 5 .456), whereas the 1-year cumulative
incidence of moderate to severe chronicGVHDwas 7%vs 8%, respectively (P 5 .673). In the CPI
cohort, the 2-year cumulative incidence of relapse appeared lower compared with the no-CPI
cohort (0 vs 20%; P 5 .054). No differences were observed in terms of overall survival (OS),
progression-free survival (PFS), and nonrelapse mortality (NRM) (at 2 years, 77% vs 71%
[P 5 .599], 78% vs 53% [P 5 .066], and 15% vs 21% [P 5 .578], respectively). By
multivariable analysis, CPI before SCT was an independent protective factor for PFS
(hazard ratio [HR], 0.32; P 5 .037). Stable disease (SD)/progressive disease (PD) was an
independent negative prognostic factor for both OS and PFS (HR, 14.3; P , .001 and HR,
14.1; P , .001, respectively) . In conclusion, CPI as a bridge to haplo-SCT seems to improve
PFS, with no impact on toxicity profile.

Files

Restricted

The record is publicly accessible, but files are restricted. <a href="https://zenodo.org/account/settings/login?next=https://zenodo.org/records/4501655">Log in</a> to check if you have access.

Request access

If you would like to request access to these files, please fill out the form below.

You need to satisfy these conditions in order for this request to be accepted:

This set of data is accessible only upon request because it includes sensitive data.

Please write your request at biblioteca@humanitas.it

You are currently not logged in. Do you have an account? Log in here

Additional details

Related works

Is supplement to
10.1182/bloodadvances.2019001336. (DOI)
32227210 (PMID)